Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 20/20 | 0.83 |
| ▸ | ITGA5 | P08648 | 20/20 | 0.83 |
| ▸ | ITGB3 | P05106 | 13/20 | 0.83 |
| ▸ | ITGAV | P06756 | 13/20 | 0.83 |
| ▸ | ITGB5 | P18084 | 9/20 | 0.79 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14453403 | 1.00 | ITGB1 (0.83) | ITGB1ITGA5ITGB3ITGAVITGB5 | |
| SCHEMBL5560195 | 0.93 | ITGB1 (0.84) | ITGB1ITGA5ITGB3ITGAVITGB5 | |
| SCHEMBL14453405 | 0.93 | ITGB1 (0.84) | ITGB1ITGA5ITGB3ITGAVITGB5 | |
| SCHEMBL14453402 | 0.92 | ITGB1 (0.93) | ITGB1ITGA5ITGB3ITGAVITGB5 | |
| SCHEMBL5560647 | 0.92 | ITGB1 (0.93) | ITGB1ITGA5ITGB3ITGAVITGB5 | |
| SCHEMBL5567125 | 0.91 | ITGB1 (0.86) | ITGB1ITGA5ITGB3ITGAVITGB5 | |
| SCHEMBL14453398 | 0.91 | ITGB1 (0.86) | ITGB1ITGA5ITGB3ITGAVITGB5 | |
| SCHEMBL14453401 | 0.91 | ITGB1 (0.79) | ITGB1ITGA5ITGB3ITGAVITGB5 | |
| SCHEMBL5565095 | 0.91 | ITGB1 (0.79) | ITGB1ITGA5ITGB3ITGAVITGB5 | |
| SCHEMBL5560796 | 0.91 | ITGB1 (1.00) | ITGB1ITGA5ITGB3ITGAVITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070155712-A1 | Compounds for the inhibition of angiogenesis and use thereof | JERINI AG (DE) | 2007-07-05 | — | — | US | claimed |
| WO-2005090329-A9 | NEW COMPOUNDS FOR THE INHIBITION OF ANGIOGENESIS AND USE OF THEREOF | JERINI AG (DE) | 2007-02-01 | — | — | WO | claimed |
| EP-1727811-A1 | NEW COMPOUNDS FOR THE INHIBITION OF ANGIOGENESIS AND USE OF THEREOF | Jerini AG (DE) | 2006-12-06 | — | — | EP | claimed |
| WO-2005090329-A1 | NEW COMPOUNDS FOR THE INHIBITION OF ANGIOGENESIS AND USE OF THEREOF | JERINI AG (DE) | 2005-09-29 | — | — | WO | claimed |
| US-8501787-B2 | Compounds for the inhibition of angiogenesis and use thereof | SHIRE ORPHAN THERAPIES GMBH (DE) | 2013-08-06 | — | — | US | disclosed |
| US-20070155712-A1 | Compounds for the inhibition of angiogenesis and use thereof | JERINI AG (DE) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155712-A1 | Compounds for the inhibition of angiogenesis and use thereof | ITGAV, VCAM1, ITGA5 | ITGB1 9/4885ITGA5 3/4885ITGB3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.